Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Bio-Optronics updates Clinical Conductor CTMS

Wednesday, January 21, 2015 01:01 PM

Bio-Optronics, a global provider of software and services to healthcare and life sciences, has updated Clinical Conductor, a collaborative and configurable CTMS for organizations managing or executing clinical trials. Clinical Conductor was fitted with new features and functionality that provide users with even more capability to connect with other research technologies and further collaborate with research partners to ensure clinical research success.

More... »


Roche acquires Trophos to expand neuromuscular disease portfolio

Wednesday, January 21, 2015 01:00 PM

Roche has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. The company has developed a proprietary cholesterol-oxime based chemistry platform. Trophos's mitochondrial targeted compounds enhance the function and survival of stressed cells by preventing mitochondrial permeability transition, a key determinant of cell death or survival.

More... »


PPD expands GMP laboratory in Ireland

Wednesday, January 21, 2015 12:59 PM

Pharmaceutical Product Development (PPD), a global CRO based in Wilmington, N.C., has expanded its good manufacturing practices (GMP) operations in Athlone, Ireland, by adding a new, state-of-the-art laboratory for cell-based assays to its existing portfolio of services at the facility. The new lab provides GMP bioassay testing with dedicated areas to support cell culture activities with multiple assay endpoint expertise.

More... »

Trovagene, Genomac expand collaboration

Wednesday, January 21, 2015 12:57 PM

Trovagene, a provider of technology for the detection and monitoring of cell-free DNA headquartered in San Diego, will expand its clinical collaboration with Genomac Research Institute in Prague, Czech Republic. Trovagene Precision Cancer Monitoring technology will be used in two prospective clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies used to treat colorectal and lung cancer.

More... »

Verified Clinical Trials, Quorum Review IRB collaborate to prevent dual enrollment

Monday, January 19, 2015 12:53 PM

Verified Clinical Trials and Quorum Review IRB have developed an expedited research subject authorization review process that reduces cost and time. Research sites, CROs and sponsors will benefit from this alliance in the effort to stop dual enrollment in clinical trials and reduce significant protocol deviations. 

More... »

Dedicated Computing joins the Intel Cluster Ready program

Monday, January 19, 2015 12:52 PM

Dedicated Computing, a Waukesha, Wis.-based global technology company, is participating in the Intel Cluster Ready program to deliver integrated high-performance computing (HPC) cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is offering a family of purpose-built analytics and storage clusters for use in bioinformatics research.

More... »

Johnson & Johnson forms Ebola vaccine development consortia

Monday, January 19, 2015 12:48 PM

Johnson & Johnson has formed a consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than $116 million from the Ebola+ program to support the development, manufacturing and patient education for the vaccine regimen.

More... »

Neuropore, UCB enter world-wide collaboration and agreement

Monday, January 19, 2015 12:45 PM

Neuropore Therapies, a wholly owned U.S. subsidiary of Austria-based Ever Neuro Pharma, and UCB, a Brussels, Belgium-based global biopharmaceutical company, have entered into a worldwide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease and related disorders. This includes NPT200-11, Neuropore’s novel small molecule that targets pathogenic alpha-synuclein, which currently is in preclinical development and is expected to enter clinical phase I in 2015.

More... »

When the Evaluator is Evaluated

Monday, January 19, 2015 08:00 AM

Regardless of the industry, or how simple or complex the profession, a consistent assessment of job performance is required to determine a professional’s ongoing proficiency.

More... »

FDA approves record 41 new drugs in 2014, over 40% for rare diseases

Friday, January 16, 2015 02:52 PM

Pharmaceutical innovation had a banner year in 2014, as the FDA approved 41 novel drugs and biologics—the largest number in 18 years and a 52% increase from the 27 approved in 2013.

More... »

CenterWatch Drugs in Clinical Trials
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs